Cholesterol lowering Rx cuts recurrence in breast cancer

Cholesterol lowering rx cuts recurrence in breast cancer

(HealthDay)—For women with early-stage, hormone receptor-positive invasive breast cancer, initiation of cholesterol-lowering medication (CLM) during endocrine therapy is associated with improved survival and distant recurrence-free intervals, according to research published online Feb. 13 in the Journal of Clinical Oncology.

Signe Borgquist, M.D., Ph.D., from Harvard Medical School in Boston, and colleagues conducted a randomized, phase III trial (BIG 1-98) involving 8,010 postmenopausal women with early-stage, hormone receptor-positive from 1998 to 2003. At study entry and every six months, systemic levels of total cholesterol and use of CLM were measured up to 5.5 years. The relationships between initiation of CLM during and outcome were assessed.

The researchers found that cholesterol levels declined during tamoxifen therapy. Most of the 789 patients who initiated CLM during endocrine therapy were from the letrozole monotherapy arm, followed by the sequential tamoxifen-letrozole, letrozole-tamoxifen, and tamoxifen monotherapy arms (318, 189, 176, and 106 patients, respectively). There were correlations between initiation of CLM during endocrine therapy and improved disease-free survival, breast cancer-free interval, and distant recurrence-free interval (hazard ratios, 0.79, 0.76, and 0.74, respectively).

"Cholesterol-lowering medication during adjuvant endocrine therapy may have a role in preventing in hormone receptor-positive ," the authors write. "We recommend that these observational results be addressed in prospective randomized trials."

Several authors disclosed financial ties to the biopharmaceutical industry.

Explore further

Presurgical endocrine therapy less toxic than chemotherapy for ER-positive breast cancer

More information: Full Text
Journal information: Journal of Clinical Oncology

Copyright © 2017 HealthDay. All rights reserved.

Citation: Cholesterol lowering Rx cuts recurrence in breast cancer (2017, February 15) retrieved 26 November 2020 from
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Feedback to editors

User comments